Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BTAI 
BioXcel Therapeutics Inc (BTAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/20/2025: BTAI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $19.8
1 Year Target Price $19.8
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -94% | Avg. Invested days 20 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.38M USD | Price to earnings Ratio - | 1Y Target Price 19.8 |
Price to earnings Ratio - | 1Y Target Price 19.8 | ||
Volume (30-day avg) 3 | Beta 0.19 | 52 Weeks Range 1.17 - 13.28 | Updated Date 10/19/2025 |
52 Weeks Range 1.17 - 13.28 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.9 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -13210% |
Management Effectiveness
Return on Assets (TTM) -68.72% | Return on Equity (TTM) -1766.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 143373554 | Price to Sales(TTM) 52.29 |
Enterprise Value 143373554 | Price to Sales(TTM) 52.29 | ||
Enterprise Value to Revenue 165.18 | Enterprise Value to EBITDA -0.75 | Shares Outstanding 19646801 | Shares Floating 13388128 |
Shares Outstanding 19646801 | Shares Floating 13388128 | ||
Percent Insiders 2.82 | Percent Institutions 9.85 |
Upturn AI SWOT
BioXcel Therapeutics Inc
Company Overview
History and Background
BioXcel Therapeutics, Inc. was founded in 2010. It is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The company's focus has evolved from broader applications of AI to a targeted approach in specific therapeutic areas, particularly mental health.
Core Business Areas
- Neuroscience: Focuses on developing therapies for acute agitation and other neuropsychiatric disorders. The lead product is BXCL501 (dexmedetomidine sublingual film).
- Immuno-oncology: This segment has been de-emphasized; however, previous research efforts aimed to leverage AI to identify novel immuno-oncology targets and develop related therapies.
Leadership and Structure
The company is led by a management team with experience in pharmaceuticals and biotechnology. Key figures include the CEO and Chief Medical Officer. The organizational structure includes research and development, commercial, and administrative functions.
Top Products and Market Share
Key Offerings
- BXCL501 (Igalmi): A sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Market share data is still emerging. Competitors include traditional antipsychotics and benzodiazepines used off-label for agitation. The revenue for 2023 was approximately 7.3 Million US Dollars.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically within neuroscience, is characterized by high unmet needs and significant market opportunities. The market for treatments for agitation and other neuropsychiatric conditions is substantial.
Positioning
BioXcel Therapeutics is positioned as an innovator leveraging AI to identify and develop novel therapies in neuroscience. Their competitive advantage lies in the novel formulation and administration of dexmedetomidine for acute agitation.
Total Addressable Market (TAM)
The TAM for acute agitation treatment is estimated to be in the billions of dollars annually. BioXcel is positioned to capture a portion of this market with Igalmi, targeting a specific segment of patients experiencing agitation related to schizophrenia or bipolar disorder.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Igalmi)
- Novel drug delivery system (sublingual film)
- AI-driven drug discovery platform
- Targeted approach to specific neuropsychiatric conditions
Weaknesses
- Limited commercial infrastructure
- Dependence on a single approved product
- Relatively small company size compared to competitors
- Past restructurings and pipeline refocusing can affect reputation
Opportunities
- Expansion of Igalmi label to other indications (e.g., agitation in dementia)
- Partnerships with larger pharmaceutical companies for commercialization
- Development of new therapies using the AI platform
- Growing awareness and acceptance of sublingual drug delivery
Threats
- Competition from existing treatments and new entrants
- Regulatory hurdles and potential setbacks in clinical trials
- Pricing and reimbursement pressures
- Potential safety concerns or adverse events associated with Igalmi
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- TEVA
- MYL
Competitive Landscape
BioXcel has a novel product in Igalmi but faces competition from established pharmaceutical companies with broader portfolios and resources. The AI platform is a potential differentiator.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by research and development progress and the approval of Igalmi.
Future Projections: Future growth is dependent on the successful commercialization of Igalmi and the development of new therapies. Analyst estimates vary, but generally project revenue growth in the coming years.
Recent Initiatives: Recent initiatives include focusing on commercializing Igalmi, cost-cutting measures, and rationalizing the pipeline.
Summary
BioXcel Therapeutics shows promise with Igalmi's approval and novel AI platform but faces financial constraints and significant competition. The company's growth depends on successful commercialization and pipeline expansion. It must manage its cash flow and navigate the regulatory landscape carefully, while the competition is strong with competitors such as LLY and ABBV. With future initiative the company has a large opportunity but the current financials make it a risky investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Press releases
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioXcel Therapeutics Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2018-03-08 | Founder, CEO, President, & Director Dr. Vimal D. Mehta Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | |
Full time employees 37 | |||
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.